BIB ProShares Ultra Nasdaq Biotechnology
Quote as of Oct 09, 2026 20:00 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 105.02 | Day Range | 106.78 – 111.39 |
| 52-Week Range | 62.72 – 126.40 | Volume | 7.33K |
| Avg Volume | 10.96K | AUM | $93.2M (Oct 12, 2026) |
| Expense Ratio | 1.19% | Yield (TTM) | 0.20% |
| NAV | 110.96 | Premium/Discount | +0.02% indicative |
| Inception | Apr 07, 2010 | Holdings | 274 |
| Issuer | ProShares | Exchange | NASDAQ |
| Category | Biotech | Index Tracked | Not stated in source data |
| CUSIP | 74347R214 | ISIN | US74347R2141 |
| Management | Passive / index-tracking (per issuer description) | ||
About this ETF
ProShares Trust - ProShares Ultra Nasdaq Biotechnology is an exchange traded fund launched and managed by ProShare Advisors LLC. It invests in public equity markets of the United States. It invests through derivatives in stocks of companies operating across health care, pharmaceuticals, biotechnology, drugs manufacturer, diagnostic development and life sciences sectors. It uses derivatives such as swaps to create its portfolio. The fund invests in growth and value stocks of companies across diversified market capitalization. The fund seeks to track 2x the daily performance of the Nasdaq Biotechnology Index, by using full replication technique. ProShares Trust - ProShares Ultra Nasdaq Biotechnology was formed on April 7, 2010 and is domiciled in the United States.
Description from the fund data provider · profile as of Oct 12, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | -1.62% | +7.83% | +36.05% | +39.11% | +69.07% | +31.89% | +4.90% | +9.61% | +17.73% |
| Total return | -1.62% | +7.83% | +36.05% | +39.12% | +69.38% | +33.08% | +5.47% | +9.91% | +17.93% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Oct 09, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 1.19% | Annual cost of a $10,000 investment | $119.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Oct 10, 2026 · portfolio reporting date from the data provider; holdings are not live positions. 256 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | Net Other Assets (Liabilities) | — | 19.91% | 18.56M | $18.6M |
| 2 | PROSHARES GENIUS MNY MKT ETF | IQMM | 18.26% | 170.00K | $17.0M |
| 3 | GILEAD SCIENCES INC | GILD | 5.20% | 32.07K | $4.8M |
| 4 | AMGEN INC | AMGN | 4.86% | 10.92K | $4.5M |
| 5 | VERTEX PHARMACEUTICALS INC | VRTX | 4.72% | 8.62K | $4.4M |
| 6 | MODERNA INC | MRNA | 3.70% | 15.34K | $3.5M |
| 7 | REGENERON PHARMACEUTICALS | REGN | 3.11% | 3.88K | $2.9M |
| 8 | ILLUMINA INC | ILMN | 1.73% | 5.80K | $1.6M |
| 9 | REVOLUTION MEDICINES INC | RVMD | 1.68% | 8.23K | $1.6M |
| 10 | BIOGEN INC | BIIB | 1.37% | 5.68K | $1.3M |
| 11 | ALNYLAM PHARMACEUTICALS INC | ALNY | 1.28% | 5.14K | $1.2M |
| 12 | ROIVANT SCIENCES LTD | ROIV | 1.06% | 27.75K | $983.4K |
| 13 | ROYALTY PHARMA PLC- CL A | RPRX | 1.04% | 17.11K | $973.8K |
| 14 | UNITED THERAPEUTICS CORP | UTHR | 0.97% | 1.65K | $905.0K |
| 15 | INCYTE CORP | INCY | 0.94% | 7.79K | $878.3K |
| 16 | ARGENX SE - ADR | ARGX | 0.93% | 1.05K | $864.6K |
| 17 | GUARDANT HEALTH INC | GH | 0.93% | 5.16K | $863.3K |
| 18 | INSMED INC | INSM | 0.91% | 8.39K | $843.9K |
| 19 | VIATRIS INC | VTRS | 0.84% | 44.12K | $778.3K |
| 20 | MEDPACE HOLDINGS INC | MEDP | 0.70% | 1.07K | $656.1K |
| 21 | EXELIXIS INC | EXEL | 0.61% | 9.52K | $569.8K |
| 22 | NEUROCRINE BIOSCIENCES INC | NBIX | 0.60% | 3.90K | $556.2K |
| 23 | JAZZ PHARMACEUTICALS PLC | JAZZ | 0.58% | 2.49K | $544.7K |
| 24 | ASCENDIS PHARMA A/S | ASND | 0.58% | 2.37K | $542.1K |
| 25 | SUMMIT THERAPEUTICS INC | SMMT | 0.58% | 30.65K | $539.1K |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | 0.20% | Paid (last 12 months) | $0.2243 |
| Frequency | Semi-Annual | SEC yield | Not provided by our data source; see the issuer page |
| Last ex-date | Sep 23, 2026 | Last payment | $0.0826 (Sep 29, 2026) |
| Growth 1Y | -74.46% | Growth 3Y / 5Y (ann.) | +124.40% / — |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Sep 23, 2026 | Sep 23, 2026 | Sep 29, 2026 | $0.0826 |
| Mar 25, 2026 | Mar 25, 2026 | Mar 31, 2026 | $0.0071 |
| Dec 24, 2025 | Dec 24, 2025 | Dec 31, 2025 | $0.1346 |
| Sep 24, 2025 | Sep 24, 2025 | Sep 30, 2025 | $0.1805 |
| Jun 25, 2025 | Jun 25, 2025 | Jul 01, 2025 | $0.1706 |
| Mar 26, 2025 | Mar 26, 2025 | Apr 01, 2025 | $0.1309 |
| Dec 23, 2024 | Dec 23, 2024 | Dec 31, 2024 | $0.3964 |
| Sep 25, 2024 | Sep 25, 2024 | Oct 02, 2024 | $0.1529 |
| Jun 26, 2024 | Jun 26, 2024 | Jul 03, 2024 | $0.2648 |
| Mar 20, 2024 | Mar 21, 2024 | Mar 27, 2024 | $0.0403 |
| Dec 20, 2023 | Dec 21, 2023 | Dec 28, 2023 | $0.0384 |
| Dec 22, 2022 | Dec 23, 2022 | Dec 30, 2022 | $0.0199 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
| Volatility 1Y / 3Y | 43.76% / 42.04% | Sharpe 1Y / 3Y | 2.02 / 1.02 |
| Max drawdown 1Y / 3Y | -16.92% / -45.31% | Sortino 1Y | 3.18 |
| Beta vs S&P 500 (3Y) | 1.52 | Correlation vs S&P 500 (1Y) | 0.43 |
| Downside deviation 1Y | 27.73% | Risk-free rate used | 4.05% (3M T-bill, FRED) |
Computed by ETF Explorer from daily dividend-adjusted closes; volatility and drawdown are annualized/period figures; S&P 500 exposure proxied by SPY. As of Oct 12, 2026. Formulas →
Liquidity
| Volume today | 7.33K | Average volume | 10.96K |
| AUM | $93.2M | Premium/Discount | +0.02% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV: an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Day | $0.00 | 0.00% | $93.2M → $93.2M |
| 1 Month | -$3.2M | -3.38% | $95.4M → $93.2M |
| 1 Week | $1.9M | +2.05% | $92.2M → $93.2M |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source; review them before investing.
Latest News for BIB
No articles mention this fund directly in the last 7 days; showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.